ARI-0002h

N/A

Report date: 2025/02/28 14:32:34

Base Information

Drug NameARI-0002h

Drug Alias NameCARTBCMA ARI-0002hHumanized CART Directed Against BCMAARI-0002h

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4]

Mechanisms of ActionAnti-BCMATumor necrosis factor receptor superfamily member 9 agonists

TargetsB-cell maturation proteinTumor necrosis factor receptor superfamily member 9

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesInstituto De Salud Carlos Iii

China Registration ClassN/A

Develop Information

Active CompaniesFondos ARI (Assistencia Recerca Intensiva)Instituto De Salud Carlos Iii

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A